Fig. 1 | Nature Communications

Fig. 1

From: Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers

Fig. 1

Pooled CRISRP/Cas9 screening strategy identifies sensitivity genes. a Schematic representation of pooled CRISPR/Cas9 screening completed in MDA-MB-361 cells. Samples were collected at the indicated time points. b Bright-field micrographs and crystal violet staining of cultured MDA-MB-361 and BT-474 cells treated with DMSO or 1 μM lapatinib. c Strategy to identify sensitivity genes. The average of two biological repeats each gene depletion: x-axis as DMSO (2 weeks) compared to T = 0, y-axis as lapatinib (2 weeks) compared to T = 0, were plotted. IGF1R, TALDO1, GATA3, TBX3, and PTK2 are indicated as the most differentially depleted genes after lapatinib treatment. d Depletion percentages of individual sgRNA constructs in indicated samples compared to T = 0

Back to article page